Abstract
Several chronic inflammatory airway diseases are characterized by an increased number of neutrophils in the airways. There is evidence that the recruitment of these neutrophils can be controlled by certain T-lymphocytes. However, the mechanisms behind this T-cell control of airway neutrophilia are poorly understood. In this review, we summarize the evidence that interleukin (IL)-17 released from T-lymphocytes of the CD45RO+ subset can link the activation of these T-cells to the recruitment and activation of neutrophils. This evidence suggests that pharmacotherapeutical modulation of neutrophilic airway inflammation can be achieved using several different strategies, including inhibition of IL-17 production by cAMP elevating agents or certain nuclear factor inhibitors, neutralization of released IL-17 protein by specific anti-IL-17-antibodies, blockade of the IL-17 receptor as well as inhibition of certain MAP kinases mediating the post receptor effects of IL-17 in airway cells. Additional studies on animals in vivo and patients, respectively, are needed to further evaluate the pharmacotherapeutical potential of these strategies.
Keywords: potential target, neutrophilia, epithelial damage, cytokine receptor, kidney carcinoma epithelial cells, airway neutrophils
Current Pharmaceutical Design
Title: IL-17 as a Potential Target for Modulating Airway Neutrophilia
Volume: 8 Issue: 20
Author(s): Martti Laan and Anders Linden
Affiliation:
Keywords: potential target, neutrophilia, epithelial damage, cytokine receptor, kidney carcinoma epithelial cells, airway neutrophils
Abstract: Several chronic inflammatory airway diseases are characterized by an increased number of neutrophils in the airways. There is evidence that the recruitment of these neutrophils can be controlled by certain T-lymphocytes. However, the mechanisms behind this T-cell control of airway neutrophilia are poorly understood. In this review, we summarize the evidence that interleukin (IL)-17 released from T-lymphocytes of the CD45RO+ subset can link the activation of these T-cells to the recruitment and activation of neutrophils. This evidence suggests that pharmacotherapeutical modulation of neutrophilic airway inflammation can be achieved using several different strategies, including inhibition of IL-17 production by cAMP elevating agents or certain nuclear factor inhibitors, neutralization of released IL-17 protein by specific anti-IL-17-antibodies, blockade of the IL-17 receptor as well as inhibition of certain MAP kinases mediating the post receptor effects of IL-17 in airway cells. Additional studies on animals in vivo and patients, respectively, are needed to further evaluate the pharmacotherapeutical potential of these strategies.
Export Options
About this article
Cite this article as:
Laan Martti and Linden Anders, IL-17 as a Potential Target for Modulating Airway Neutrophilia, Current Pharmaceutical Design 2002; 8 (20) . https://dx.doi.org/10.2174/1381612023393864
DOI https://dx.doi.org/10.2174/1381612023393864 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Association of Palmitoylethanolamide with Luteolin Decreases Neuroinflammation and Stimulates Autophagy in Parkinson's Disease Model
CNS & Neurological Disorders - Drug Targets A Review on the New Indication of Nucleoside Reverse Transcriptase Inhibitors (NRTIs) in the Treatment of Coronavirus Disease 2019
Infectious Disorders - Drug Targets Epidrugs in the Immunotherapy of Cutaneous and Uveal Melanoma
Anti-Cancer Agents in Medicinal Chemistry ABC Transporters in Multidrug Resistance and Pharmacokinetics, and Strategies for Drug Development
Current Pharmaceutical Design Acknowledgment to Contributors
Recent Patents on Inflammation & Allergy Drug Discovery An Insight of Molecular Mechanisms and Patents of Biomarkers of Human Papilloma Virus Associated with Cancer : A Review
Recent Patents on Biomarkers Micronized Purified Flavonoid Fraction (MPFF)*: A Review of its Pharmacological Effects, Therapeutic Efficacy and Benefits in the Management of Chronic Venous Insufficiency
Current Vascular Pharmacology The Role of P2Y<sub>12</sub> Receptor and Activated Platelets During Inflammation
Current Drug Targets Delivery Systems for RNA Interference Therapy: Current Technologies and Limitations
Current Gene Therapy The Epidemiology and Health Effects of Tobacco Use
Current Pediatric Reviews Glucans as Biological Response Modifiers
Endocrine, Metabolic & Immune Disorders - Drug Targets Plant Cohesins, Common Themes and Unique Roles
Current Protein & Peptide Science Insights into Peptide Mediated Antibiofilm Treatment in Chronic Wound: A Bench to Bedside Approach
Current Protein & Peptide Science Kinin Receptors in Vascular Biology and Pathology
Current Vascular Pharmacology Protein Engineering for Improved Health: Technological Perspectives
Current Protein & Peptide Science In Silico Identification of Natural Lead Molecules from the Genus of Phyllanthus Against Hepatitis B Virus Reverse Transcriptase
The Natural Products Journal Expression and Function of the Leukocyte Integrins in Medicine
Current Genomics The Mechanisms Involved in Obesity-Induced Male Infertility
Current Diabetes Reviews Vascular Wall Responses to Angioplasty and Stenting: Endothelial Injury, Neointimal Hyperplasia and the Process of Restenosis
Vascular Disease Prevention (Discontinued) Roles of Perilipins in Diseases and Cancers
Current Genomics